Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascentage to Start US Trial of Treatment for Drug-Resistant Leukemia

publication date: Jul 22, 2019

Ascentage Pharma, a Suzhou company specializing in apoptosis drugs, was approved to start a US Phase Ib clinical trial of its BCR-ABL tyrosine kinase inhibitor to treat drug-resistant chronic myeloid leukemia (CML). HQP1351 was designed to address acquired drug resistance caused by imatinib (Gleevec), which occurs in 20-30% of all CML patients. Ascentage's candidate is an oral, third-gen BCR-ABL TKI designed to target a broad spectrum of BCR-ABL mutants, including the T315I mutation. HQP1351 is the sixth Ascentage candidate accepted to start US trials. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital